StreetInsider.com News Articles

Form RW RenovoRx, Inc.

Fri, 16 Oct 2026 07:00:00 -0400

si-local-file:///var/storage/secattach/20261016/27195555.html

RenovoRx enrolls first patient in UVM-sponsored PRISM-TAMP trial

Wed, 07 Oct 2026 08:33:33 -0400

RenovoRx, Inc. (Nasdaq: RNXT) announced that the first patient has been enrolled in PRISM-TAMP, an investigator-initiated trial sponsored by the University of Vermont exploring the company's Trans-Arterial Micro-Perfusion (TAMP) platform as a pre-surgical treatment for borderline resectable pancreatic ductal adenocarcinoma (PDAC).

The trial, formally titled "PDAC Regression and Intraoperative Surgical Margin With Neoadjuvant TAMP," is evaluating gemcitabine delivered via RenovoRx's FDA-cleared RenovoCath device directly near the tumor site before surgery. A second patient was reported to be progressing toward treatment one week after the trial began. UVM plans to enroll approximately 10 patients total, and the study is registered on ClinicalTrials.gov

RenovoRx Advances TAMP™ into Borderline Resectable Pancreatic Cancer with First Patient Enrolled in Investigator-Initiated PRISM-TAMP Trial

Wed, 07 Oct 2026 08:30:00 -0400

University of Vermont-Sponsored IIT Explores TAMP in a New Clinical Setting: TAMP Utilization Prior to Surgical Resection

MOUNTAIN VIEW, Calif., Oct. 07, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath^®, a patented, FDA-cleared drug-delivery device, announced today that the first patient has enrolled in PRISM-TAMP, “PDAC Regression and Intraoperative Surgical Margin With Neoadjuvant TAMP,” an investigator-initiated trial (IIT) sponsored by the University of Vermont (UVM). One week after the IIT began, a second patient is also progressing toward TAMP

RenovoRx Advances TAMP™ into Borderline Resectable Pancreatic Cancer with First Patient Enrolled in Investigator-Initiated PRISM-TAMP Trial

Wed, 07 Oct 2026 08:30:00 -0400

University of Vermont-Sponsored IIT Explores TAMP in a New Clinical Setting: TAMP Utilization Prior to Surgical Resection

Form 4 RenovoRx, Inc. For: Oct 01 Filed by: Macfarlane K. Angela

Fri, 02 Oct 2026 17:01:00 -0400

si-local-file:///var/storage/secattach/20261002/27143320.html

Form 4 RenovoRx, Inc. For: Oct 01 Filed by: Marton Laurence

Fri, 02 Oct 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20261002/27143306.html

Form 4 RenovoRx, Inc. For: Oct 01 Filed by: Spiegel Robert J.

Fri, 02 Oct 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20261002/27143308.html

Form 4 RenovoRx, Inc. For: Oct 01 Filed by: RYAN UNA S

Fri, 02 Oct 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20261002/27143312.html

RenovoRx case series published on pancreatic cancer drug delivery

Thu, 01 Oct 2026 08:33:35 -0400

RenovoRx, Inc. (Nasdaq: RNXT) announced the publication of a peer-reviewed case series in Case Reports in Oncology examining the use of its Trans-Arterial Micro-Perfusion (TAMP) platform for delivering chemotherapy in patients with locally advanced pancreatic cancer (LAPC).

The case series, led by researchers at Hackensack Meridian Health's Jersey Shore University Medical Center, describes two patients with unresectable LAPC who received intra-arterial gemcitabine delivered via RenovoCath, RenovoRx's FDA-cleared drug-delivery device. Both patients showed reductions in CA 19-9, a marker used to monitor pancreatic cancer activity, and favorable changes on imaging, including resolution of vascular narrowing, without major procedural complications.

Gregory Tiesi, MD, lead

RenovoRx's drug-delivery device featured in peer-reviewed cancer study

Thu, 01 Oct 2026 08:31:47 -0400

RenovoRx, Inc. (Nasdaq: RNXT) announced the publication of a peer-reviewed case series in Case Reports in Oncology describing the use of its Trans-Arterial Micro-Perfusion (TAMP) platform and RenovoCath device in two patients with locally advanced pancreatic cancer (LAPC).

The case series, authored by researchers at Hackensack Meridian Health's Jersey Shore University Medical Center, describes two patients whose tumors were not surgically removable due to vascular involvement after prior treatment. Both patients received intra-arterial gemcitabine delivered via the TAMP platform using RenovoCath. According to the publication, both patients showed reductions in CA 19-9, a marker used to monitor pancreatic cancer activity, along

RenovoRx Announces Peer-Reviewed Publication Highlighting the TAMP™ Platform's Potential to Improve Chemotherapeutic Delivery for Locally Advanced Pancreatic Cancer

Thu, 01 Oct 2026 08:30:00 -0400

MOUNTAIN VIEW, Calif., Oct. 01, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life-sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, today announced the publication of a peer-reviewed case series in Case Reports in Oncology from researchers at Hackensack Meridian Health’s Jersey Shore University Medical Center.

The publication describes two patients with locally advanced pancreatic cancer (LAPC), whose tumors were not surgically removable due to significant complex blood vessel involvement despite receiving extensive prior treatment. Both patients underwent chemotherapy utilizing TAMP-mediated local intra-arterial

RenovoRx Announces Peer-Reviewed Publication Highlighting the TAMP™ Platform's Potential to Improve Chemotherapeutic Delivery for Locally Advanced Pancreatic Cancer

Thu, 01 Oct 2026 08:30:00 -0400

RenovoRx Announces Peer-Reviewed Publication Highlighting the TAMP™ Platform's Potential to Improve Chemotherapeutic Delivery for Locally Advanced Pancreatic Cancer

Thu, 01 Oct 2026 08:30:00 -0400

Case Series Reports Tumor Treatment Response, Significant Tumor Marker Reduction, and Changes on Imaging After Treatment with TAMP in Patients with Unresectable LAPC

MOUNTAIN VIEW, Calif., Oct. 01, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life-sciences company developing innovative targeted oncology therapies and commercializing RenovoCath^®, a patented, FDA-cleared drug-delivery device, today announced the publication of a peer-reviewed case series in Case Reports in Oncology from researchers at Hackensack Meridian Health’s Jersey Shore University Medical Center.

The publication describes two patients with locally advanced pancreatic cancer (LAPC), whose tumors were not

RenovoRx Announces Peer-Reviewed Publication Highlighting the TAMP™ Platform's Potential to Improve Chemotherapeutic Delivery for Locally Advanced Pancreatic Cancer

Thu, 01 Oct 2026 08:30:00 -0400

Case Series Reports Tumor Treatment Response, Significant Tumor Marker Reduction, and Changes on Imaging After Treatment with TAMP in Patients with Unresectable LAPC

MOUNTAIN VIEW, Calif., Oct. 01, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life-sciences company developing innovative targeted oncology therapies and commercializing RenovoCath^®, a patented, FDA-cleared drug-delivery device, today announced the publication of a peer-reviewed case series in Case Reports in Oncology from researchers at Hackensack Meridian Health’s Jersey Shore University Medical Center.

The publication describes two patients with locally advanced pancreatic cancer (LAPC), whose tumors were not

Form 4 RenovoRx, Inc. For: Sep 10 Filed by: VOLL MARK

Tue, 15 Sep 2026 06:07:00 -0400

si-local-file:///var/storage/secattach/20260915/27060674.html

RenovoRx to Present at H.C. Wainwright 28th Annual Global Investment Conference, September 14th-16th

Wed, 02 Sep 2026 08:30:00 -0400

MOUNTAIN VIEW, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath^®, a patented, FDA-cleared drug-delivery device, today announced that Shaun Bagai, Chief Executive Officer, and Mark Voll, Chief Financial Officer, will present at the H.C. Wainwright 28th Annual Global Investment Conference. The conference will be held at the Lotte New York Palace Hotel in New York City, September 14-16, 2026.

Mr. Bagai and Mr. Voll will discuss RenovoRx’s record second quarter revenue, driven by

RenovoRx to Present at H.C. Wainwright 28th Annual Global Investment Conference, September 14th-16th

Wed, 02 Sep 2026 08:30:00 -0400

Mr. Bagai and Mr. Voll will discuss RenovoRx’s record second quarter revenue, driven by

RenovoRx publishes PK/PD data from pancreatic cancer drug trial

Tue, 25 Aug 2026 08:31:35 -0400

RenovoRx, Inc. (NASDAQ: RNXT) announced the publication of pharmacokinetic and pharmacodynamic (PK/PD) data from a sub-study of its Phase III TIGeR-PaC clinical trial in the journal Cancer Chemotherapy and Pharmacology.

The sub-study compared intra-arterial gemcitabine delivered via the company's TAMP (Trans-Arterial Micro-Perfusion) platform using its RenovoCath device against standard intravenous gemcitabine in 16 patients with locally advanced pancreatic cancer (LAPC) across six clinical sites. Eleven patients received intra-arterial gemcitabine and five received intravenous gemcitabine.

Key findings from the study include a targeted extraction ratio of 0.511, indicating approximately 51% of the intra-arterially delivered gemcitabine was extracted at the tumor site before entering

RenovoRx Highlights Peer-Reviewed Publication of Pharmacokinetic and Pharmacodynamic (PK/PD) Data Supporting TAMP™ Platform’s Targeted Drug-Delivery in Locally Advanced Pancreatic Cancer

Tue, 25 Aug 2026 08:30:00 -0400

PK/PD Data is from a Sub-Study in the Phase III TIGeR-PaC Clinical Trial

The Study Shows Approximately 51% Tumor-Site Drug Extraction, Decreased Systemic Exposure, and Significant Correlation Between Drug Metabolite Levels and Tumor Marker Reduction

MOUNTAIN VIEW, Calif., Aug. 25, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath^®, a patented, FDA-cleared drug-delivery device, today announced the publication of pharmacokinetic and pharmacodynamic (PK/PD) data from a sub-study of its ongoing Phase III TIGeR-PaC clinical trial

RenovoRx Highlights Peer-Reviewed Publication of Pharmacokinetic and Pharmacodynamic (PK/PD) Data Supporting TAMP™ Platform’s Targeted Drug-Delivery in Locally Advanced Pancreatic Cancer

Tue, 25 Aug 2026 08:30:00 -0400

PK/PD Data is from a Sub-Study in the Phase III TIGeR-PaC Clinical Trial

The Study Shows Approximately 51% Tumor-Site Drug Extraction, Decreased Systemic Exposure, and Significant Correlation Between Drug Metabolite Levels and Tumor Marker Reduction

RenovoRx Highlights Peer-Reviewed Publication of Pharmacokinetic and Pharmacodynamic (PK/PD) Data Supporting TAMP™ Platform’s Targeted Drug-Delivery in Locally Advanced Pancreatic Cancer

Tue, 25 Aug 2026 08:30:00 -0400

PK/PD Data is from a Sub-Study in the Phase III TIGeR-PaC Clinical Trial

The Study Shows Approximately 51% Tumor-Site Drug Extraction, Decreased Systemic Exposure, and Significant Correlation Between Drug Metabolite Levels and Tumor Marker Reduction

RenovoRx Highlights Peer-Reviewed Publication of Pharmacokinetic and Pharmacodynamic (PK/PD) Data Supporting TAMP™ Platform’s Targeted Drug-Delivery in Locally Advanced Pancreatic Cancer

Tue, 25 Aug 2026 08:30:00 -0400

PK/PD Data is from a Sub-Study in the Phase III TIGeR-PaC Clinical Trial

The Study Shows Approximately 51% Tumor-Site Drug Extraction, Decreased Systemic Exposure, and Significant Correlation Between Drug Metabolite Levels and Tumor Marker Reduction

RenovoRx regains Nasdaq minimum bid price compliance

Fri, 21 Aug 2026 08:30:24 -0400

RenovoRx, Inc. (NASDAQ: RNXT) announced it has received written notification from Nasdaq confirming the company has regained compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market.

Nasdaq's Listing Qualifications Staff notified RenovoRx on Aug. 20, 2026, that the closing bid price of its common stock was at $1.00 per share or greater for 10 consecutive business days from Aug. 6 through Aug. 19, 2026. The company has regained compliance with Nasdaq Listing Rule 5550(a)(2), and Nasdaq confirmed the matter is closed. RenovoRx had originally received a deficiency notice from Nasdaq on Dec. 31, 2025.

The notification

RenovoRx Regains Compliance with Nasdaq Minimum Bid Price Requirement

Fri, 21 Aug 2026 08:30:00 -0400

MOUNTAIN VIEW, Calif., Aug. 21, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath^®, a patented, FDA-cleared drug-delivery device, today announced that it has received written notification from The Nasdaq Stock Market LLC (“Nasdaq”) confirming that the Company has regained compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market.

On August 20, 2026, the Nasdaq Listing Qualifications Staff notified RenovoRx in writing that the closing bid price of its common stock was at $1.00

RenovoRx Regains Compliance with Nasdaq Minimum Bid Price Requirement

Fri, 21 Aug 2026 08:30:00 -0400

On August 20, 2026, the Nasdaq Listing Qualifications Staff notified RenovoRx in writing that the closing bid price of its common stock was at $1.00